Ind-Swift Laboratories Ltd (INDSWFTLAB) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Ind-Swift Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
Audio recording of earning conference call held on 04.11.2026 on un-audited financial results for the quarter ended 30.09.2026.
Audio / Video · 05 Nov 2026, 12:56 am
Ind-Swift Laboratories Releases Q2 FY26-27 Earnings Call Audio Recording Ind-Swift Laboratories announced that the audio recording for its earnings conference call held on 4th Nov'26 is available on the company's website. The call discussed financial results for the quarter ended 30th Sep'26 (Q2 FY26-27). The company confirmed that the written transcript of the earnings call will be submitted to the stock exchanges and uploaded to its website in due course.
Please find enclosed investor presentation on un-audited financial results for the quarter ended September 30, 2026
Investor Presentation · 04 Nov 2026, 5:11 pm
Ind-Swift Laboratories Reports Strong Q2FY27 Growth Driven by FDF Platform Scale-Up Ind-Swift Laboratories reported standalone revenue of ₹242.49 crore for Q2FY27, up 25.18% QoQ, with operating EBITDA increasing 27.04% QoQ to ₹42.33 crore (18.02% margin) and PAT reaching ₹31.03 crore. For H1FY27, revenue reached ₹436.20 crore (up 31.83% YoY) and PAT grew 3.3x YoY to ₹55.47 crore. Following its transition to a pure-play Finished Dosage Formulation (FDF) player, the net-debt-free company is funding a ₹250 crore capex via internal accruals, targeting >50% FY27 revenue growth and a medium-term revenue CAGR of 20-25%.
Monitoring Agency Report for the quarter ended September 30, 2026 in respect of receipt of funds raised through preferential issue of 70,00,000 Fully Convertible Warrants
Others (Uncategorized) · 03 Nov 2026, 8:26 pm
Ind-Swift Laboratories Reports Preferential Warrant Proceeds Utilization for Q2FY27 CARE Ratings issued its Monitoring Agency Report for Ind-Swift Laboratories regarding its Rs 137.20 crore preferential warrant issue allotted on 17th Sep'26. As of 30th Sep'26, the company raised Rs 34.30 crore, utilizing Rs 15.60 crore and leaving Rs 18.70 crore unutilized in ICICI Bank fixed deposits. Deployments included Rs 6.315 crore for facility expansion, Rs 4.853 crore in Dubai subsidiary ISLL Middle East, Rs 3.989 crore for working capital, Rs 0.335 crore for R&D, and Rs 0.108 crore for GCP. CARE noted zero material deviations.
Monitoring Agency Report for the quarter ended September 30, 2026 in respect of funds raised through Preferential Issue 2.6 Cr Fully Convertible Warrants
Others (Uncategorized) · 03 Nov 2026, 8:17 pm
Ind-Swift Laboratories Completes Preferential Issue Proceeds Utilization in Q2FY27 Ind-Swift Laboratories fully utilized its preferential issue proceeds as of 30th Sep'26, concluding with a final deployment of Rs. 3.77 crore in Q2FY27 toward business expansion. Total funds raised and utilized reached Rs. 255.61 crore out of the targeted Rs. 314.60 crore, as 65 lakh warrants lapsed due to non-conversion by Saral Incorporated VCC Sub Fund 1, causing a Rs. 58.99 crore shortfall. The company confirmed that this shortfall will be funded via internal accruals, with unutilized issue proceeds standing at zero.
Please find enclosed Schedule of Analyst / Investor Meet which will be held on Wednesday, November 04, 2026, at 04.00 P.M. IST in respect of financial results of the Company for the quarter ....
Intimation · 04 Nov 2026, 4:00 pm
Ind-Swift Laboratories Schedules Q2 FY27 Earnings Call on 4th Nov'26 Ind-Swift Laboratories Limited will host its Q2 FY27 earnings conference call on 4th Nov'26 at 04:00 PM IST to discuss financial results for the quarter ended 30th Sep'26. Management participants include CFO Gagan Agarwal, DGM Finance Shalika Malhotra, and VP Corporate Affairs & CS Pardeep Verma. The call is hosted in partnership with ConfideLeap Partners and requires prior registration (Webinar ID: 917 8169 7026, Passcode: 042197).
Press Release in respect of Unaudited Financial Results (Standalone & Consolidated) for the second quarter and half year ended September 30, 2026
Press Release · 30 Oct 2026, 11:21 pm
Ind-Swift Laboratories Reports Strong Q2 FY27 Results Driven by Formulations Shift Ind-Swift Laboratories reported robust standalone Q2 FY27 performance, with operating income growing 50.15% YoY to ₹234.89 crore and operating EBITDA surging nearly 5x YoY to ₹42.33 crore, expanding margins by 1,256 bps YoY to 18.02%. PAT rose 3.54x YoY to ₹31.03 crore with a 13.21% margin. Sequentially, revenue and operating EBITDA grew 26.23% and 27.02% QoQ, respectively. Growth was driven by operational scaling in finished dosage formulations, expanding CDMO partnerships, and raw material cost efficiencies, supported by a net-debt-free balance sheet.
Please refer attached pdf
Others (Uncategorized) · 30 Oct 2026, 2:15 am
Ind-Swift Laboratories Reports Nil Deviation in Convertible Warrants Fund Utilization Ind-Swift Laboratories confirmed zero deviation in proceeds utilization for the quarter ended 30th Sep'26 regarding its preferential issue of 70 lakh fully convertible warrants allotted on 17th Sep'26. Out of the total issue size of Rs. 137.20 crore, the company raised Rs. 34.30 crore and deployed Rs. 15.60 crore. Key capital outlays include Rs. 6.31 crore for manufacturing expansion and warehousing, Rs. 4.85 crore for subsidiary investments, Rs. 3.99 crore toward working capital, Rs. 0.33 crore for R&D, and Rs. 0.11 crore for general corporate purposes.
Please refer attached pdf
Others (Uncategorized) · 30 Oct 2026, 2:14 am
Ind-Swift Laboratories Reports Nil Deviation and Full Preferential Issue Proceeds Utilization Ind-Swift Laboratories confirmed zero deviation in utilizing proceeds from its 30th Aug'24 preferential issue of 2.60 crore convertible warrants. Total realizable proceeds were revised to ₹255.61 crore (against the original issue size of ₹314.60 crore) as ₹58.99 crore became non-receivable following an allottee's failure to exercise conversion rights by 28th Feb'26. The company has fully deployed the received ₹255.61 crore across business expansion (₹113.54 crore), general corporate purposes (₹75.00 crore), working capital (₹39.60 crore), and subsidiary investments (₹27.47 crore) as of 30th Sep'26.
Please find enclosed copy of financial results
Financial Result · 29 Oct 2026, 8:37 pm
Please find enclosed outcome of the Board Meeting held on October 29, 2026
Outcome · 29 Oct 2026, 8:29 pm
Ind-Swift Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 29 Oct 2026, 8:29 pm
Ind-Swift Laboratories Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 24,046 (+51.6% YoY | +25.6% QoQ) ■ EBITDA: 4,546 (+508.5% YoY | +36.0% QoQ) ■ EBITDA Margin (%): 18.9 (+1420 bps YoY | +144 bps QoQ) ■ PAT: 3,422 (+328.3% YoY | +38.6% QoQ) ■ EPS (INR): 3.92 (+308.3% YoY | +38.0% QoQ)
IND-SWIFT LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 29 Oct 2026, 5:30 am
Ind-Swift Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve inter alia, to Consider ....
Intimation · 29 Oct 2026, 5:30 am
Ind-Swift Laboratories Schedules Board Meeting for Q2 FY27 Financial Results Ind-Swift Laboratories Ltd. has scheduled a meeting of its Board of Directors on 29th Oct'26. The board will inter-alia consider, approve, and take on record the standalone and consolidated un-audited financial results of the company for the quarter and half-year ended 30th Sep'26. The trading window closure for dealing in company securities was previously intimated on 28th Sep'26.
To consider and approve the financial results for the quarter and half year ended September 30, 2026
Intimation · 29 Oct 2026, 5:30 am
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Essix Biosciences Ltd & Others
Acquisition/ Disposal of Shares · 12 Oct 2026, 11:08 pm
Essix Biosciences Converts Warrants into Ind-Swift Laboratories Equity Shares Promoter group entity Essix Biosciences acquired 14.00 lakh equity shares (Rs 10 face value) of Ind-Swift Laboratories on 8th Oct'26 through the conversion of fully convertible warrants. The acquisition represents 1.58% of pre-issue and 1.49% of diluted share capital. Post-allotment, Essix Biosciences' direct holding rose to 3.43 crore shares (38.80%), while the total promoter and PAC holding increased to 43.84% of total share capital (47.18% diluted), leaving 56.00 lakh unexercised warrants. Target company paid-up equity capital expanded to Rs 88.36 crore.
Please refer attached pdf.
Others (Uncategorized) · 12 Oct 2026, 11:05 pm
Essix Biosciences Increases Stake in Ind-Swift Laboratories via Warrant Conversion Essix Biosciences Limited, part of the promoter group of Ind-Swift Laboratories Limited, acquired 14,00,000 equity shares (1.58% voting capital) on 8th Oct'26 through the conversion of preferential convertible warrants. Post-allotment, Essix Biosciences' direct shareholding increased from 37.81% (3,28,82,521 shares) to 38.80% (3,42,82,521 shares), while combined promoter and PAC voting rights rose to 43.84% (4,43,34,278 shares). Ind-Swift's total paid-up voting equity expanded to Rs. 88.36 cr (8,83,61,558 shares of Rs. 10 each), with total diluted capital standing at Rs. 93.96 cr.
Please find outcome of Preferential Issue Committee Meeting held on Oct. 08, 2026
Others · 09 Oct 2026, 12:10 am
Ind-Swift Laboratories Approves Equity Allotment on Warrant Conversion Ind-Swift Laboratories Limited's Preferential Issue Committee approved the allotment of 14,00,000 equity shares (face value ₹10 each) on 8th Oct'26 upon conversion of fully convertible warrants issued at ₹196 each to promoter entity Essix Biosciences Limited. The conversion followed receipt of the balance 75% consideration of ₹147 per warrant, aggregating ₹20.58 Cr. Consequently, the company's paid-up equity share capital increased from ₹86.71 Cr (8,67,11,558 shares) to ₹86.96 Cr (8,69,61,558 shares).
Please find enclosed scrutiniser''s report along with voting results for the 31st AGM, held on 30th September, 2026
Annual General Meeting · 05 Oct 2026, 11:57 pm
Please find enclosed proceedings of the 31st Annual General Meeting of the company held on Wednesday, 30th Sept., 2026.
Annual General Meeting · 30 Sept 2026, 11:52 pm
Please refer attached pdf
Others (Uncategorized) · 29 Sept 2026, 12:36 am
Ind-Swift Laboratories Mandates KYC and PAN Submission for Physical Security Holders Pursuant to SEBI circulars, Ind-Swift Laboratories has dispatched intimations to physical shareholders requiring the mandatory submission and updating of PAN, KYC, bank details, and nominations via its RTA, Alankit Limited. Non-compliant shareholders will be barred from lodging grievances or availing RTA services. Additionally, effective 1st Apr'24, all corporate payments—including dividends, interest, and redemptions—for such folios are strictly payable through electronic mode only upon complete submission of the required details.
Please find enclosed Schedule of Analyst / Investor Meet scheduled to be held on Tuesday, 29th September, 2026, at 01.00 P.M. IST
Intimation · 23 Sept 2026, 10:47 pm
Ind-Swift Laboratories Schedules Virtual Analyst Meet with Arihant Capital Ind-Swift Laboratories Ltd. announced a virtual group investor meeting scheduled with Arihant Capital on 29th Sep'26 at 01:00 PM IST, pursuant to Regulation 30 of SEBI LODR Regulations, 2015. The company stated that no Unpublished Price Sensitive Information (UPSI) will be shared during the interaction, and the schedule remains subject to changes due to exigencies.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Essix Biosciences Ltd & Others
Acquisition/ Disposal of Shares · 22 Sept 2026, 4:43 pm
Essix Biosciences Acquires 70 Lakh Warrants in Ind-Swift Laboratories via Preferential Issue Essix Biosciences Limited, part of the promoter group of Ind-Swift Laboratories Limited, acquired 70,00,000 fully convertible warrants on a preferential basis for cash on 17th Sep'26. The warrants represent 7.45% of the target company's total diluted share capital. Following this acquisition, the aggregate promoter and PACs holding stands at 42.93% of post-issue share capital (3,73,34,278 equity shares) and will increase to 47.18% on a fully diluted basis (4,43,34,278 shares/warrants) upon complete conversion, expanding the total diluted voting capital to 9,39,61,558 equity shares.
Please refer attached pdf.
Others (Uncategorized) · 21 Sept 2026, 11:41 pm
Essix Biosciences Acquired 70 Lakh Warrants in Ind-Swift Laboratories Promoter entity Essix Biosciences acquired 70,00,000 fully convertible warrants in Ind-Swift Laboratories on a preferential basis for cash on 17th Sep'26, representing 7.45% of diluted capital. Post-transaction, Essix Biosciences and persons acting in concert hold 3,73,34,278 equity shares (42.93% voting capital) and 70,00,000 warrants, raising their combined diluted stake from 43.06% to 47.18%. Following the preferential allotment and an ESOP exercise of 2,50,000 shares, the company's total diluted share capital stands at Rs. 93.96 crore, comprising 9,39,61,558 equity shares.
Outcome of Preferential Issue Committee for Allotment of 70,00,000 Fully Convertible Warrants on Preferential Basis
Others (Uncategorized) · 17 Sept 2026, 11:15 pm
Ind-Swift Laboratories Allots 70 Lakh Convertible Warrants to Promoter Group Ind-Swift Laboratories approved the allotment of 70,00,000 fully convertible warrants on a preferential basis to promoter group entity Essix Biosciences Limited on 17th Sep'26. The warrants were issued at Rs. 196 each (including a premium of Rs. 186). The company received the upfront 25% subscription price of Rs. 49 per warrant, aggregating to Rs. 34.30 crore. The preferential allotment follows shareholder approval obtained on 5th Aug'26 and in-principle approval from BSE and NSE on 16th Sep'26.
Please find enclosed Annual Report for the FY 2025-26.
Others (Uncategorized) · 06 Sept 2026, 2:19 am